Results 51 to 60 of about 4,153 (212)

Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study

Journal of Comparative Effectiveness Research, 2023
Aim: Finerenone is safe and efficacious for treating patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D). Evidence on the use of finerenone in clinical practice is lacking.
David Vizcaya, Csaba P Kovesdy, Andres Reyes, Elena Pessina, Pau Pujol, Glen James, Nikolaus G Oberprieler   +6 more
doaj   +1 more source

Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease

Metabolism Open
Introduction: Diabetic kidney disease (DKD) is an important complication of diabetes as it results in end-stage renal disease; hence, several drugs have been developed for its treatment.
Akira Mima, Yuta Saito, Keishi Matsumoto, Takahiro Nakamoto, Shinji Lee   +4 more
doaj   +1 more source

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone

CPT: Pharmacometrics & Systems Pharmacology, 2022
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist that recently demonstrated its efficacy to delay chronic kidney disease (CKD) progression and reduce cardiovascular events in patients with CKD and type 2 diabetes.
Thomas Wendl, Sebastian Frechen, Michael Gerisch, Roland Heinig, Thomas Eissing   +4 more
doaj   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Dearomatization with Axial‐to‐Central Chirality Conversion

European Journal of Organic Chemistry, EarlyView.
Atropisomers are exciting synthetic targets with unique properties, which find applications in many fields of chemistry. However, considering them as substrates is not very frequent, notably in the context of dearomatization reaction. We wish to discuss the different strategies for the dearomatization of aromatic atropisomers with axial‐to‐central ...
Morgane Mando, Clément Lemaitre, Thierry Constantieux, Xavier Bugaut   +3 more
wiley   +1 more source

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy [PDF]

, 2021
INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes ...
, Agarwal, Rajiv, Anker, Stefan D., Bakris, George L., Chan, Juliana C.N., Filippatos, Gerasimos, Joseph, Amer, Kooy, Adriaan, McCafferty, Kieran, Pitt, Bertram, Rossing, Peter, Ruilope, Luis M., Scheerer, Markus F., Schernthaner, Guntram, Scott, Charlie, Wanner, Christoph   +15 more
core   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [PDF]

, 2017
The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and ...
Bonventre, J, Coresh, J, Donner, J-A, Eckardt, K-U, Fogo, AB, Fox, CS, Gansevoort, RT, Heerspink, HJL, ISN Global Kidney Health Summit participants, Jardine, M, Kasiske, B, Kretzler, M, Köttgen, A, Levey, AS, Levin, A, Luyckx, VA, Mehta, R, Moe, O, Obrador, G, Pannu, N, Parikh, CR, Perkovic, V, Pollock, C, Stenvinkel, P, Tonelli, M, Tuttle, KR, Wheeler, DC   +26 more
core  

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source